Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06568601 · ClinicalTrials.gov registry record · NA
Pharmacogenomic Informed Statin Prescribing
A NA study of Hypercholesterolemia, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- NA
- Development phase
- 410
- Enrollment target
- 2
- Study locations
NCT06568601 is a NA study of Hypercholesterolemia that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 410 participants, below the 810-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (49% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06568601, a NA study of Hypercholesterolemia, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- NA
- Development phase
- 410 participants
- Enrollment target
- 2
- Study locations
Study Summary
Statins are the most cost-effective medications to lower cholesterol and cardiovascular disease (CVD) risk. However, many patients at high-risk for CVD do not accept or adhere to statins. This gap in patient's use of statins limits the full impact of these effective medications resulting in higher cholesterol levels and CVD risk. The main barriers to using statins are patients' perceived lack of benefit, excess risk of statin toxicity as well as their misperceptions of their CVD risk. Statin pharmacogenomic testing - an application of precision medicine - is a readily available, feasible, and inexpensive intervention that addresses this barrier by using genetic testing to identify the nearly 1 out of 2 patients with enhanced benefit and/or reduced risk of statin toxicity or increased risk for CVD. By communicating statin pharmacogenomic test results to Veterans at high-risk for CVD not taking statin therapy, the investigators aim to improve patients' perceptions of their risk of CVD and statins and, in turn, their acceptance of and adherence to statins to reduce their cholesterol levels and CVD risk.
Conditions Studied
Interventions
- GENETIC Pharmacogenetic and polygenic risk testing
- OTHER Active control
Study Locations (2)
Indiana
- Richard L. Roudebush VA Medical Center, Indianapolis, IN - Indianapolis
North Carolina
- Durham VA Medical Center, Durham, NC - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 410 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2028-07-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06568601
The ClinicalTrials.gov registry entry for NCT06568601 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 410 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 810-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (49% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 2 interventions - of which Pharmacogenetic and polygenic risk testing is the first listed.
NCT06568601 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Indiana, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06568601 about?
NCT06568601 is a clinical study titled "Pharmacogenomic Informed Statin Prescribing". Statins are the most cost-effective medications to lower cholesterol and cardiovascular disease (CVD) risk. However, many patients at high-risk for CVD do not accept or adhere to statins. This gap in patient's use of statins limits the full impact of these effective medications resulting in higher c...
What is the current status of trial NCT06568601?
This trial is currently recruiting. It is a NA study. The enrollment target is 410 participants. The study started on 2025-04-01. Estimated completion is 2028-07-28.
What conditions does trial NCT06568601 study?
This clinical trial studies the following conditions: Hypercholesterolemia.
What interventions are being tested in trial NCT06568601?
The interventions under investigation include: Pharmacogenetic and polygenic risk testing (GENETIC), Active control (OTHER).
Who is sponsoring clinical trial NCT06568601?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06568601 being conducted?
This trial has 2 study locations across Indiana, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
RECRUITING · NA
-
A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.
ACTIVE NOT RECRUITING · NA
-
Effect of Diabetes Mellitus on Cholesterol Metabolism
COMPLETED · NA
-
Evaluating the Efficacy of Pediatric Lipid Screening Alerts
COMPLETED · NA
-
Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients
COMPLETED · NA
-
Diets Enriched With Pecans
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.